Abstract 300P
Background
Cervical cancer is the leading cause of death among gynecological cancers and ranks seventh among all types of cancer affecting women in Vietnam, with about 15.7% of cases occurring in women under 40 years old. Post-operative radiation therapy can cause ovarian dysfunction and related complications even in patients who had the ovaries transposed. This study aims to evaluate the extent of radiation exposure to the transposed ovaries and its impact on ovarian function in cervical cancer patients at the Ho Chi Minh City Oncology Hospital, who have undergone ovary transposition and received adjuvant radiation therapy.
Methods
We studied retrospectively radiation dosages and ovarian functions in cervix cancer patients who had ovarian transposition at our hospital from Jan 2020 to Dec 2021. We included patients under 45 years who completed at least 6 months of radiation therapy, and collected data on their medical records and radiotherapy planning software. Ovarian function was evaluated by FSH and estradiol levels before and after treatment. We used Epidata and Stata software to analyze the data and tested correlations using t-test pairing, Fisher test, and Spearman correlation.
Results
A total of 22 patients were included in the study. The mean radiation dose to the ovaries was positively correlated with PTV, ovarian position, stage and radiation technique. Of the 15 patients whose ovarian function was investigated after radiotherapy, 5 patients (33.33%) preserved ovarian function. The function preserved groups had lower ovarian radiation dosage. Table: 300P
Mean ovarian dosage (Gy) +/- SD (n) | Range | p | |
StageIB2IB3IIA1IIIC1p | 6,14 +/- 6,5 (16)14,26 +/- 12,14 (12)11,21 +/- 10,65 (4)15,86 +/- 15,29 (8) | 0,854-190.946-35,8670,963-21,130,885-45,562 | p=0,21 |
Ovarian position:Inside pelvis outside pelvis | 20,63 +/- 11,92 (13)6,4 +/- 7,88 (27) | 3,532-42,560,85-29,57 | 0,008 |
FunctionPreservedNot preserved | 1,29 +/- 2,13 (5)20,54 +/- 11,23 (10) | 1,09 -3,24,231-42,562 | 0,001 |
Technique3D CRTIMRT | 6,46 +/- 9,89 (27)19,45 +/- 9,03 (13) | 42,58 -0,8535,87 -5,29 | 0,0001 |
Conclusions
Transposed ovary location and mean ovarian dose are important factors in determining ovarian function outcomes. 3D CRT was better than IMRT, possibly due to scatter doses and inadequate ovarian dose constraints during radiation therapy planning. Increasing sample size and establishing a consistent practice protocol could enhance the validity of this study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ho Chi Minh City University of Medicine and Pharmacy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract